ストックスクリーナーアプリを入手
7.0025
4.16%
0.2725
前日終値:
$6.73
開ける：
$6.78
24時間の取引高:
51,946
Relative Volume:
0.37
時価総額：
$48.73M
収益：
$46.74M
当期純損益:
$-114.33M
株価収益率:
-5.4283
EPS:
-1.29
ネットキャッシュフロー:
$-21.04M
1週間 パフォーマンス:
+9.53%
1か月 パフォーマンス:
+46.35%
6か月 パフォーマンス:
-57.31%
1年 パフォーマンス:
-89.78%
1日の値動き範囲:
$6.73
$7.20
1週間の範囲:
$6.17
$7.20
52週間の値動き範囲:
$3.60
$73.50
Scilex Holding Company Stock (SCLX) Company Profile
名前
Scilex Holding Company
セクター
電話
(650) 516-4310
住所
960 SAN ANTONIO ROAD, PALO ALTO
SCLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
7.01 | 34.77M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
790.21 | 698.13B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
165.22 | 374.84B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
190.27 | 335.21B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
119.11 | 240.33B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
67.28 | 309.44B | 43.59B | 15.04B | 10.74B | 3.3766 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-27 | 開始されました | D. Boral Capital | Buy |
| 2024-10-16 | 開始されました | Alliance Global Partners | Buy |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-16 | 開始されました | B. Riley Securities | Buy |
| 2023-10-13 | 開始されました | B. Riley Securities | Buy |
| 2023-10-09 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Scilex Holding Company (SCLX) 最新ニュース
How Scilex Holding Company stock performs during market volatilitySafety First Trading Signals - Newser
Why Scilex Holding Company Equity Warrant stock attracts strong analyst attention200 Percent Gain Alert - Newser
What makes Scilex Holding Company stock price move sharplyWeekly Big Movers - Newser
Why Scilex Holding Company stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
What makes Scilex Holding Company Equity Warrant stock price move sharplyTop Momentum Stock Pick - Newser
How Scilex Holding Company Equity Warrant stock performs during market volatilityFree Access to Investment Community - Newser
Scilex (NASDAQ:SCLX) Trading 1.1% Higher – Here’s What Happened - Defense World
Even With A 27% Surge, Cautious Investors Are Not Rewarding Scilex Holding Company's (NASDAQ:SCLX) Performance Completely - simplywall.st
Scilex (NASDAQ:SCLXW) Trading Up 0.1% – What’s Next? - Defense World
Scilex Holding Company(NasdaqCM: SCLX) added to Russell 3000E Growth Index - MarketScreener
SCLX registers 1.594M shares & 1.403M warrants; directors re-elected | SCLXW SEC FilingForm 424B3 - Stock Titan
Scilex Holding Company Concludes 2025 Annual Stockholders Meeting - TipRanks
Scilex (SCLX) Board defers dividend record date; uncertainty remains | MGIH SEC FilingForm 6-K - Stock Titan
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal - The Manila Times
Scilex reports publication on Gloperba dosing adjustments - TipRanks
Scilex Postpones Annual Meeting Due to Quorum Issue - TipRanks
Scilex (NASDAQ:SCLX) Stock Price Down 2.8% – What’s Next? - Defense World
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - The Manila Times
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL - GlobeNewswire Inc.
New Non-Opioid Pain Treatment SP-102 Demonstrates Superior Efficacy in Latest Clinical Analysis - Stock Titan
Scilex Holding 2025 Q1 Earnings Misses Targets as Net Income Worsens by 7% - AInvest
Scilex Bio signs binding term sheet with NeuroBiogen - TipRanks
Scilex Updates Director Compensation Following Stock Split - TipRanks
Scilex adjusts director compensation post-stock split - Investing.com
Scilex (SCLX) Expected to Announce Quarterly Earnings on Monday - Defense World
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - GlobeNewswire
New Clinical Data: Scilex's Non-Opioid SP-102 Shows Promising Results for Chronic Back Pain Treatment - Stock Titan
Scilex Regains Compliance With Nasdaq Listing Rule; Shares Rise - marketscreener.com
Scilex Holding Company Regains Compliance with Nasdaq Minimum Closing Bid Price Requirement - Nasdaq
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewswire
Scilex Holding Company’s Market Journey: Closing Weak at 0.24, Down -2.01 - DWinneX
Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks
Scilex Holding Company Announces New Record Date for Preferred Stock Dividend - Nasdaq
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - The Manila Times
Scilex Holding Company Announces Change in Record Date for - GlobeNewswire
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - Yahoo Finance
Scilex Holding Amends Merger Agreement with Denali By Investing.com - Investing.com Canada
Scilex Holding Amends Merger Agreement with Denali - Investing.com Australia
SCLX stock touches 52-week low at $5.8 amid market challenges - Investing.com
Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 - Seeking Alpha
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis - The Manila Times
Scilex Gets FDA Orphan Drug Label for Colchicine for Pericarditis - marketscreener.com
Scilex Gets Orphan Drug Designation for Its Version of Colchicine - marketscreener.com
Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire
Scilex Holding announces 1-for-35 reverse stock split By Investing.com - Investing.com Canada
What Does the Market Think About Scilex Holding?Scilex Holding (NASDAQ:SCLX) - Benzinga
Scilex Holding announces 1-for-35 reverse stock split - Investing.com Australia
Canada approves Scilex’s migraine solution ELYXYB - Investing.com
Scilex Holding Company (SCLX) 財務データ
収益
当期純利益
現金流量
EPS
Scilex Holding Company (SCLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ji Henry | Executive Chairperson |
Oct 31 '24 |
Buy |
0.94 |
8,888 |
8,351 |
320,161 |
| SHAH JAISIM | See Remarks |
Oct 29 '24 |
Buy |
0.99 |
32,000 |
31,670 |
109,333 |
| Followwill Dorman | Director |
Oct 18 '24 |
Buy |
0.99 |
1,000 |
990 |
2,300 |
| Chun Jay | Director |
Oct 18 '24 |
Buy |
0.95 |
5,000 |
4,750 |
112,500 |
| Wu Yue Alexander | Director |
Oct 17 '24 |
Buy |
0.95 |
20,000 |
18,992 |
25,000 |
| Lemus David | Director |
Oct 17 '24 |
Buy |
0.90 |
2,000 |
1,800 |
2,000 |
| Ji Henry | Executive Chairperson |
Oct 17 '24 |
Buy |
0.97 |
10,000 |
9,710 |
60,070 |
| SHAH JAISIM | See Remarks |
Oct 16 '24 |
Buy |
0.99 |
30,000 |
29,751 |
77,333 |
| Ma Stephen Hoi | Chief Financial Officer |
Oct 16 '24 |
Buy |
0.97 |
6,700 |
6,499 |
22,840 |
1.29%
大文字化:
|
ボリューム (24 時間):